



A Pfizer Company

SAFETY DATA SHEET

Revision date: 13-Feb-2019

Version: 1.3

Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Filgrastim-aafi (Hospira, Inc.)

Trade Name: NIVESTYM; NIVESTIM

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not Classified

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

SAFETY DATA SHEET

Material Name: Filgrastim-aafi (Hospira, Inc.)
Revision date: 13-Feb-2019

Page 2 of 8
Version: 1.3

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Filgrastim	121181-53-1	Not Listed	Repr. 2 (H361d) STOT RE 1 (H372)	<0.1
Sodium Acetate	127-09-3	204-823-8	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Sorbitol crystalline - NF	50-70-4	200-061-5	Not Listed	*
Water for Injection	7732-18-5	231-791-2	Not Listed	*
Polysorbate 80	9005-65-6	500-019-9	Not Listed	*

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

SAFETY DATA SHEET

Material Name: Filgrastim-aafi (Hospira, Inc.)
Revision date: 13-Feb-2019

Page 3 of 8
Version: 1.3

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Filgrastim

Pfizer Occupational Exposure Band (OEB): OEB 4 (control exposure to the range of 1ug/m³ to <10ug/m³)

Sodium Acetate

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, or other engineering controls to maintain airborne levels within the OEB range.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

SAFETY DATA SHEET

Material Name: Filgrastim-aafi (Hospira, Inc.)
Revision date: 13-Feb-2019

Page 4 of 8
Version: 1.3

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Hands:	Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)
Eyes:	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)
Skin:	Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)
Respiratory protection:	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Liquid	Color:	Colourless
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	Soluble
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)	

Sorbitol crystalline - NF

No data available

Sodium Acetate

No data available

Water for Injection

No data available

Polysorbate 80

No data available

Filgrastim

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):	No data available
Vapor Pressure (kPa):	No data available
Vapor Density (g/ml):	No data available
Relative Density:	No data available
Viscosity:	No data available

Flammability:

Autoignition Temperature (Solid) (°C):	No data available
Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

SAFETY DATA SHEET

Material Name: Filgrastim-aafi (Hospira, Inc.)
Revision date: 13-Feb-2019

Page 5 of 8
Version: 1.3

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Known Clinical Effects: Adverse effects associated with therapeutic use include bone pain, muscle pain, Headache, drowsiness, lethargy, dizziness, nausea, vomiting, diarrhea, shortness of breath (dyspnea), neutropenia, hematological effects

Acute Toxicity: (Species, Route, End Point, Dose)

Sorbitol crystalline - NF

Mouse Oral LD50 17,800 mg/kg
Rat Para-periosteal LD50 7100mg/kg

Sodium Acetate

Rat Oral LD 50 3500 mg/kg
Mouse Oral LD 50 4960mg/kg

Polysorbate 80

Rat Intravenous LD 50 1790 mg/kg
Mouse Oral LD 50 25 g/kg

Filgrastim

Rat Oral LD50 > 3 mg/kg
Mouse Oral LD50 > 3mg/kg
Rat Intravenous LD50 > 3mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Filgrastim

13 Week(s) Rat Intravenous 115 µg/kg/day LOAEL Bone
52 Week(s) Rat Intraperitoneal 57.5 µg/kg/day LOAEL Bone, Spleen
52 Week(s) Monkey Intraperitoneal 115 µg/kg/day LOAEL Spleen, Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Filgrastim

Reproductive & Fertility Rat No route specified 500 µg/kg/day NOAEL No effects at maximum dose

SAFETY DATA SHEET

Material Name: Filgrastim-aafi (Hospira, Inc.)
Revision date: 13-Feb-2019

Page 6 of 8
Version: 1.3

11. TOXICOLOGICAL INFORMATION

Embryo / Fetal Development	Rat	Intravenous	20 ug/kg/day	NOAEL	Fetotoxicity
Embryo / Fetal Development	Rabbit	No route specified	80 ug/kg/day	LOAEL	Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Filgrastim

Bacterial Mutagenicity (Ames) Bacteria Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

SAFETY DATA SHEET

Material Name: Filgrastim-aafi (Hospira, Inc.)
Revision date: 13-Feb-2019

Page 7 of 8
Version: 1.3

15. REGULATORY INFORMATION

Filgrastim

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	developmental toxicity 2/27/2001
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

Sorbitol crystalline - NF

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-061-5

Water for Injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

Polysorbate 80

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	500-019-9

Sodium Acetate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	204-823-8

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child
Specific target organ toxicity, repeated exposure-Cat.1; H372 - Causes damage to organs through prolonged or repeated exposure

Data Sources: Publicly available toxicity information.

SAFETY DATA SHEET

Material Name: Filgrastim-aafi (Hospira, Inc.)
Revision date: 13-Feb-2019

Page 8 of 8
Version: 1.3

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Revision date: 13-Feb-2019

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet